Cargando…
Adalimumab and Infliximab in Crohn’s disease - real life data from a national retrospective cohort study
ABSTRACT: Aim: to compare the efficacy and safety of Adalimumab(ADA) and Infliximab(IFX), in a large Romanian population and to identify predictors of response. Methods We performed a national retrospective cohort study including 265 patients (136 ADA, 129 IFX) between 2008-2014. Binary logistic reg...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medical University Publishing House Craiova
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256158/ https://www.ncbi.nlm.nih.gov/pubmed/30568821 http://dx.doi.org/10.12865/CHSJ.42.02.01 |
_version_ | 1783374092138708992 |
---|---|
author | PREDA, C. FULGER, L. GHEORGHE, L. GHEORGHE, C. GOLDIS, A. TRIFAN, A. TANTAU, M. TANTAU, A. NEGREANU, L. MANUC, M. CIJEVSCHI-PRELIPCEAN, C. IACOB, R. TIERANU, C. MEIANU, C. DICULESCU, M. |
author_facet | PREDA, C. FULGER, L. GHEORGHE, L. GHEORGHE, C. GOLDIS, A. TRIFAN, A. TANTAU, M. TANTAU, A. NEGREANU, L. MANUC, M. CIJEVSCHI-PRELIPCEAN, C. IACOB, R. TIERANU, C. MEIANU, C. DICULESCU, M. |
author_sort | PREDA, C. |
collection | PubMed |
description | ABSTRACT: Aim: to compare the efficacy and safety of Adalimumab(ADA) and Infliximab(IFX), in a large Romanian population and to identify predictors of response. Methods We performed a national retrospective cohort study including 265 patients (136 ADA, 129 IFX) between 2008-2014. Binary logistic regression was performed with the statistical program Minitab. Results: Patients were half women, with a median age of 36, a median disease duration of 2.5 years, 80% received Azathioprine. Mean therapy duration was 20 months in ADA group and 36 months in IFX group. Complete response to Adalimumab respectively Infliximab was recorded in 77%vs.65%, secondary loss of response in 18%vs.28%, statistically comparable. We failed to identify predictors of response. In 79.2%of patients with secondary loss of response to ADA, the dose was escalated, 12.5% were switched to Infliximab. In 70%of patients that lost response to IFX, the dose was increased, 30% were switched to Adalimumab. Conclusions: Adalimumab and Infliximab have similar efficacy, with a complete response rate of~70%. In case of secondary loss of response to IFX, the best solution is to switch to ADA, with 83% response rate, while in case of secondary loss of response to ADA, increasing the dose leads to 84 % response rate. |
format | Online Article Text |
id | pubmed-6256158 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Medical University Publishing House Craiova |
record_format | MEDLINE/PubMed |
spelling | pubmed-62561582018-12-19 Adalimumab and Infliximab in Crohn’s disease - real life data from a national retrospective cohort study PREDA, C. FULGER, L. GHEORGHE, L. GHEORGHE, C. GOLDIS, A. TRIFAN, A. TANTAU, M. TANTAU, A. NEGREANU, L. MANUC, M. CIJEVSCHI-PRELIPCEAN, C. IACOB, R. TIERANU, C. MEIANU, C. DICULESCU, M. Curr Health Sci J Original Paper ABSTRACT: Aim: to compare the efficacy and safety of Adalimumab(ADA) and Infliximab(IFX), in a large Romanian population and to identify predictors of response. Methods We performed a national retrospective cohort study including 265 patients (136 ADA, 129 IFX) between 2008-2014. Binary logistic regression was performed with the statistical program Minitab. Results: Patients were half women, with a median age of 36, a median disease duration of 2.5 years, 80% received Azathioprine. Mean therapy duration was 20 months in ADA group and 36 months in IFX group. Complete response to Adalimumab respectively Infliximab was recorded in 77%vs.65%, secondary loss of response in 18%vs.28%, statistically comparable. We failed to identify predictors of response. In 79.2%of patients with secondary loss of response to ADA, the dose was escalated, 12.5% were switched to Infliximab. In 70%of patients that lost response to IFX, the dose was increased, 30% were switched to Adalimumab. Conclusions: Adalimumab and Infliximab have similar efficacy, with a complete response rate of~70%. In case of secondary loss of response to IFX, the best solution is to switch to ADA, with 83% response rate, while in case of secondary loss of response to ADA, increasing the dose leads to 84 % response rate. Medical University Publishing House Craiova 2016 2016-06-28 /pmc/articles/PMC6256158/ /pubmed/30568821 http://dx.doi.org/10.12865/CHSJ.42.02.01 Text en Copyright © 2016, Medical University Publishing House Craiova http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an open-access article distributed under the terms of a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Public License, which permits unrestricted use, adaptation, distribution and reproduction in any medium, non-commercially, provided the new creations are licensed under identical terms as the original work and the original work is properly cited. |
spellingShingle | Original Paper PREDA, C. FULGER, L. GHEORGHE, L. GHEORGHE, C. GOLDIS, A. TRIFAN, A. TANTAU, M. TANTAU, A. NEGREANU, L. MANUC, M. CIJEVSCHI-PRELIPCEAN, C. IACOB, R. TIERANU, C. MEIANU, C. DICULESCU, M. Adalimumab and Infliximab in Crohn’s disease - real life data from a national retrospective cohort study |
title | Adalimumab and Infliximab in Crohn’s disease - real life data from a national retrospective cohort study |
title_full | Adalimumab and Infliximab in Crohn’s disease - real life data from a national retrospective cohort study |
title_fullStr | Adalimumab and Infliximab in Crohn’s disease - real life data from a national retrospective cohort study |
title_full_unstemmed | Adalimumab and Infliximab in Crohn’s disease - real life data from a national retrospective cohort study |
title_short | Adalimumab and Infliximab in Crohn’s disease - real life data from a national retrospective cohort study |
title_sort | adalimumab and infliximab in crohn’s disease - real life data from a national retrospective cohort study |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256158/ https://www.ncbi.nlm.nih.gov/pubmed/30568821 http://dx.doi.org/10.12865/CHSJ.42.02.01 |
work_keys_str_mv | AT predac adalimumabandinfliximabincrohnsdiseasereallifedatafromanationalretrospectivecohortstudy AT fulgerl adalimumabandinfliximabincrohnsdiseasereallifedatafromanationalretrospectivecohortstudy AT gheorghel adalimumabandinfliximabincrohnsdiseasereallifedatafromanationalretrospectivecohortstudy AT gheorghec adalimumabandinfliximabincrohnsdiseasereallifedatafromanationalretrospectivecohortstudy AT goldisa adalimumabandinfliximabincrohnsdiseasereallifedatafromanationalretrospectivecohortstudy AT trifana adalimumabandinfliximabincrohnsdiseasereallifedatafromanationalretrospectivecohortstudy AT tantaum adalimumabandinfliximabincrohnsdiseasereallifedatafromanationalretrospectivecohortstudy AT tantaua adalimumabandinfliximabincrohnsdiseasereallifedatafromanationalretrospectivecohortstudy AT negreanul adalimumabandinfliximabincrohnsdiseasereallifedatafromanationalretrospectivecohortstudy AT manucm adalimumabandinfliximabincrohnsdiseasereallifedatafromanationalretrospectivecohortstudy AT cijevschiprelipceanc adalimumabandinfliximabincrohnsdiseasereallifedatafromanationalretrospectivecohortstudy AT iacobr adalimumabandinfliximabincrohnsdiseasereallifedatafromanationalretrospectivecohortstudy AT tieranuc adalimumabandinfliximabincrohnsdiseasereallifedatafromanationalretrospectivecohortstudy AT meianuc adalimumabandinfliximabincrohnsdiseasereallifedatafromanationalretrospectivecohortstudy AT diculescum adalimumabandinfliximabincrohnsdiseasereallifedatafromanationalretrospectivecohortstudy |